Allena Pharmaceuticals, Inc.·3

Nov 1, 9:36 PM ET

HBM BioCapital II LP 3

3 · Allena Pharmaceuticals, Inc. · Filed Nov 1, 2017

Insider Transaction Report

Form 3
Period: 2017-11-01
Holdings
  • Series C Convertible Preferred Stock

    Common Stock (140,841 underlying)
  • Series B Convertible Preferred Stock

    Common Stock (1,426,061 underlying)
Footnotes (2)
  • [F1]The Series B Convertible Preferred Stock is convertible into Common Stock of the Issuer on a 4.174-to-1 basis at any time at the holder's election, and has no expiration. The Series B Convertible Preferred Stock will automatically convert into Common Stock of the Issuer upon the closing of the Issuer's initial public offering.
  • [F2]The Series C Convertible Preferred Stock is convertible into Common Stock of the Issuer on a 4.174-to-1 basis at any time at the holder's election, and has no expiration. The Series C Convertible Preferred Stock will automatically convert into Common Stock of the Issuer upon the closing of the Issuer's initial public offering.

Documents

1 file
  • 3
    edgar.xmlPrimary

    FORM 3 -